Research Article

Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Lei Shi, Nan Min, Fei Wang, and Qing-Yun Xue

Department of Orthopaedics, Beijing Hospital, National Center of Gerontology, 100730 Beijing, China

Correspondence should be addressed to Qing-Yun Xue; xueqinyun2018@163.com

Received 29 March 2019; Accepted 1 August 2019; Published 19 November 2019

Academic Editor: Alberto Grassi

Copyright © 2019 Lei Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To investigate the comparative efficacies of the five most commonly used bisphosphonates for the secondary prevention of osteoporotic fractures in a Bayesian network meta-analysis. Methods. Five databases and the reference lists of all acquired articles from inception to July 2017 were searched. A Bayesian random-effects model was employed, and vertebral, hip and nonvertebral nonhip fractures were assessed by odds ratios (ORs) and 95% credible intervals. Furthermore, with respect to each endpoint, rank probabilities for each bisphosphonate were evaluated using the surface under the cumulative ranking curve (SUCRA) value. Results. Thirteen eligible studies were identified involving 11,822 patients with osteoporotic fractures. Overall in the pairwise meta-analyses, bisphosphonate use significantly reduced the risk of new vertebral, hip, and nonvertebral nonhip fractures, with ORs and 95% confidence intervals of 0.56 (0.49–0.64), 0.69 (0.48–0.98), and 0.82 (0.70–0.97), respectively. In network meta-analyses, significant differences were found between placebo and any one of the five bisphosphonates for new vertebral fractures. The rank probability plot and the SUCRA calculation results suggested that alendronate was the best intervention (14.6%) for secondary prevention of vertebral fractures, followed by zoledronate (15.3%) and etidronate (22.1%). In terms of the incidence of new hip fractures, alendronate was associated with the lowest incidence (18.5%), followed by zoledronate (43.1%) and risedronate (52.5%). However, zoledronate ranked lowest (16.6%) regarding the incidence of new nonvertebral nonhip fractures, followed by risedronate (23.8%) and alendronate (44.1%). Conclusions. Bisphosphonates show significant efficacy for secondary prevention of new vertebral fractures, and alendronate is most likely to be successful at secondary prevention of vertebral and hip fractures compared with the other four bisphosphonates.

1. Introduction

Osteoporosis, which primarily affects postmenopausal women and the elderly population, is characterized by low bone mineral density and decreased bone strength and is the leading cause of fragility fractures, namely, osteoporotic fractures, including vertebral, hip, and nonhip nonvertebral fractures [1, 2]. Osteoporotic fractures result in health and life quality deterioration, which in turn creates a heavy burden for patients and health system. Beyond the age of approximately 50 years, 22% of men, and 50% of women will experience an osteoporotic fracture. As a consequence, these patients are at an increased risk of several adverse outcomes, such as subsequent fracture, morbidity, and mortality [3, 4].

Hence, prevention of osteoporotic fractures is the main therapeutic target in osteoporosis treatment, and medication is a crucial approach, with bisphosphonates being the most commonly prescribed modality [5]. In the United Kingdom, about 10% of females aged 70 years or older with osteoporosis are prescribed bisphosphonates, making it one of the most frequently prescribed drug class in this patient population [6–8].

A large number of randomized controlled trials (RCTs) have demonstrated the effectiveness of different bisphosphonates for fracture prevention [9–16], but little is known about the comparative efficacies of different bisphosphonates for the prevention of secondary fractures. A network meta-analysis can be used to integrate all RCTs that compare different
biphosphonates directly or with placebo while fully preserving randomization [17].

Therefore, we aimed to assess the efficacies of the five most commonly used biphosphonates (alendronate, ibandronate, risedronate, zoledronate, and etidronate) for the secondary prevention of osteoporotic fractures via an integrated analysis of all available direct and indirect evidence in a Bayesian network meta-analysis.

### 2. Materials and Methods

#### 2.1. Search Strategy

Relevant studies published from database inception to July, 2017 were retrieved from the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed MEDLINE, Embase, Chinese National Knowledge Infrastructure (CNKI), and Chinese Wanfang Data Knowledge Service Platform. The keywords used in the searches were: osteoporotic fractures, biphosphonates (alendronate, ibandronate, risedronate zoledronate, and etidronate), and secondary prevention. We searched PubMed MEDLINE with the use of the combination of medical subject headings (MeSH) and keywords. Two reviewers (LS and FW) independently conducted the initial search through the step of screening all retrieved titles and abstracts. Irrelevant reports were excluded, while the full text of the studies included for eligibility was reviewed. We also manually checked the reference lists of all acquired articles for additional relevant studies.

#### 2.2. Inclusion and Exclusion Criteria

The academic studies identified for this network meta-analysis had to meet the following criteria: (1) designed as a RCT; (2) included postmenopausal women or men over 50 years with existing osteoporotic fractures; (3) included a comparison between at least one of the five biphosphonates, including alendronate, ibandronate, risedronate, zoledronate, and etidronate, with placebo or another of the investigated biphosphonates; (4) reported clinical outcomes including new vertebral fractures, new hip fractures, or new nonvertebral non-hip fractures, with new vertebral fractures defined as the primary outcome, and new nonvertebral fractures defined as a secondary outcome; (5) provided sufficient and qualified data that could be extracted from original academic studies; and (5) had a treatment duration of at least 24 months.

Studies were excluded if: (1) the patients did not have osteoporotic fractures; (2) the study was not a RCT or a conference abstract or paper; (3) sufficient data were unavailable; (4) the treatment duration was less than 24 months; and (5) included patients with secondary osteoporosis (glucocorticoid-induced osteoporosis, etc.).

#### 2.3. Data Extraction and Quality Assessment

Two reviewers (LS and NM) independently extracted the data from the included academic studies using a standardized data collection form. Discrepancies between the two reviewers were settled by discussion with a third reviewer (QYX) to reach agreement. The authors of the relevant studies were also contacted if additional information was required. New vertebral fracture was chosen as the primary outcome, since it is the most frequently encountered osteoporotic fracture [2, 18], while new hip fractures and nonvertebral non-hip fractures were secondary endpoints. Detailed information from the original articles was extracted, including the study design, name of the first author, year of publication, sample size of enrolled patients, mean patient age, intervention, preparations and doses, treatment cycle, duration, and clinical outcomes (new vertebral fractures, new hip fractures, or new nonvertebral non-hip fractures). The methodological quality of the eligible articles was assessed using the risk of bias as detailed in the Cochrane Collaboration Handbook.

#### 2.4. Statistical Analysis

A pair-wise meta-analysis combining studies addressing the same clinical outcome was performed using STATA 14 (Stata Corp, College Station, TX), and clinical outcomes were assessed using odds ratios (ORs) with 95% confidential intervals (CIs). Significant heterogeneity was expressed by $I^2 > 50\%$, which was calculated using the DerSimonian and Laird method with a random effects model; otherwise, the Mantel-Haenszel method with a fixed-effects model was used.

Except for pair-wise meta-analyses, a network meta-analysis for indirect treatment comparison was conducted within a Bayesian framework with a random-effects model [19], which enabled specific incorporation of multiple treatments constructed from two studies that have one of the five biphosphonates in common and combined indirect and direct evidence for any provided pair of biphosphonates and certain clinical results. ORs with 95% credible intervals (Crls), calculated by the Markov chain Monte Carlo method, were obtained using WinBUGS (MRC Bio-statistics Unit, Cambridge, UK). Then, we performed a sensitivity analysis to verify the robustness of the clinical outcomes.

In addition, the consistency between indirect and direct comparisons was assessed through the comparison of ORs from the pair-wise meta-analyses and the pooled ORs from the network meta-analyses. The node-splitting method, calculating the inconsistency of the model for evaluating the consistency, was performed using the software program R (version 3.4.0), in which the Bayesian $P$ value is considered as the inconsistency [20]. Based on biphosphonates' rank probabilities, we sorted the included biphosphonates according to each clinical outcome. The sum of the rank probabilities for each biphosphonate was assessed by the surface under the cumulative ranking curve (SUCRA) [21]. A lower SUCRA for a given intervention indicates that it is more efficient for the secondary prevention of osteoporotic fractures. Additionally, sensitivity analyses were performed to evaluate the influence of each study on the overall results.

### 3. Results

#### 3.1. Study Characteristics

Of 3869 records that were initially identified from the literature search, 13 academic papers remained after removal of duplicates and screening by scanning titles, abstracts, and full texts, with a total of 11,822 patients with existing vertebral fractures[13–16, 22–30], of
which postmenopausal women accounted for more than 98%. A flow chart of study selection is presented in Figure 1. The patients enrolled received pharmacotherapy using alendronate, ibandronate, risendronate, zoledronate, or etidronate. The baseline characteristics and primary outcomes of eligible studies were categorized by the bisphosphonates used and are summarized in Table 1. The robustness of the results of pairwise meta-analysis was further verified through a sensitivity analysis and funnel plot as shown in Figures S1–S3 with credible results and no obvious publication bias.

The quality of the included trials was moderate to high, as shown in Table 1, with 61.5% of the studied papers considered as having a low risk of bias for blinding of outcome assessors [14, 16, 23, 24, 26–29], 100% for blinding of patients [13–16, 22–30], and 38.5% for incomplete outcome data [15, 22, 27, 28, 30]. None of the studied papers was judged to have a high risk of bias for any item of the methodological quality evaluated, except for allocation concealment, for which 12 (92.3%) of the 13 studied papers were judged as an unclear risk of bias [13–16, 22–25, 27–30].

3.2. **Pairwise Meta-Analysis.** Compared with placebo, bisphosphonates significantly reduced the risk of new vertebral, hip, and nonvertebral nonhip fractures, with ORs and 95% CIs of 0.56 (0.49–0.64), 0.69 (0.48–0.98), and 0.82 (0.70–0.97), respectively (Figure S1).

3.3. **Network Meta-Analysis.** Figure 2 shows the network diagram of eligible studies. As the primary outcome of this Bayesian analysis, the incidence of new vertebral fractures was compared among the treatments (Figure 3). From the 13 papers selected for including direct or indirect comparisons, we found that all five bisphosphonates were more effective than placebo (alendronate: OR = 0.45, 95% CrI 0.28–0.68; ibandronate: OR = 0.64, 95% CrI 0.45–0.88; risendronate: OR = 0.58, 95% CrI 0.42–0.79; zoledronate: OR = 0.31, 95% CrI for Figure 1: Flow diagram of review process.
### Table 1: Baseline characteristics of the trials included in the present study.

| Study                  | Design | Mean age, (t1/t2) yrs | Interventions                                      | No (t1/t2) | Study duration | Outcome* | Allocation concealment | Blinding (patients/outcome assessors) | Risk of bias | Incomplete outcome data |
|------------------------|--------|-----------------------|----------------------------------------------------|------------|----------------|-----------|------------------------|--------------------------------------|--------------|------------------------|
| Nakamura et al., 2016  | RCT    | 74/74                 | Zoledronate (5 mg/yr)                              | Placebo    | 301/296        | 2 yrs     | Un unclear            | Low/Low                              | High         |                        |
| Wang et al., 2016      | RCT    | 67.3/68.5             | Alendronate (70 mg/w 2 yrs)                        | Placebo    | 37/37          | 2 yrs     | 1                      | Un unclear                          | Low/Low      | Low                    |
| Ji et al., 2013        | RCT    | 67.3/65.5             | Alendronate (70 mg/w 2 yrs)                        | Placebo    | 40/40          | 2 yrs     | 1, 2, 3               | Un unclear                          | Low/Low      | Low                    |
| Nakamura et al., 2013  | RCT    | 72.2/72.9/73          | Ibandronate (1 mg/m) vs (0.5 mg/m) Risedronate (2.5 mg/d) | 382/376/376 | 3 yrs          | 1         | Un unclear            | Low/Low                              | High         |                        |
| Recker et al., 2004    | RCT    | 67/67                 | Ibandronate (1 mg/3 ms) vs (0.5 mg/3 ms) Ibandronate (2.5 mg/d) vs (20 mg/qod intermittent) | Placebo    | 1912/975       | 3 yrs     | 1, 2, 3               | Un unclear                          | Low/Low      | High                   |
| Chesnut et al., 2004   | RCT    | 69/69                 | Ibandronate (2.5 mg/d) Placebo                     | Placebo    | 977/975        | 3 yrs     | 1, 2, 3               | Un unclear                          | Low/Low      | Low                    |
| Kushida et al., 2004   | RCT    | 71.2/72.6             | Alendronate (5 mg/d 3 yrs)                         | Placebo    | 90/80          | 3 yrs     | 1                      | Un unclear                          | Low/Low      | Low                    |
| Reginster et al., 2000 | RCT    | 71/71                 | Risedronate (5 mg/d)                               | Placebo    | 408/408        | 3 yrs     | 1, 2, 3               | Un unclear                          | Low/Unclear  | Low                    |
| Harris et al., 1999    | RCT    | 66/66                 | Risedronate (5 mg/d)                               | Placebo    | 821/820        | 3 yrs     | 1, 2, 3               | Low                                  | Low/Low      | High                   |
| Clemmesen et al., 1997 | RCT    | 67/68/70              | Risedronate (2.5 mg/d) vs (2.5 mg/d, cyclic)       | Placebo    | 44/44          | 3 yrs     | 1                      | Un unclear                          | Low/Unclear  | Unclear                |
| Black et al., 1996     | RCT    | 71/71                 | Alendronate (5 mg/d 2 yrs, 10 mg/d 1 yr)           | Placebo    | 1022/1005      | 3 yrs     | 1, 2, 3               | Un unclear                          | Low/Low      | High                   |
| Watts et al., 1990     | RCT    | 64.7/65.7             | Etidronate (400 mg/d, intermittent)                | Placebo    | 105/104        | 2 yrs     | 1, 2, 3               | Un unclear                          | Low/Low      | High                   |
| Storm et al., 1990     | RCT    | 68.3/68.3             | Etidronate (400 mg/d, intermittent)                | Placebo    | 33/33          | 150 weeks | 1, 2, 3               | Un unclear                          | Low/Unclear  | Low                    |

RCT: Randomized controlled trials; No: patients' number; t1: treatment group; t2: control group; yrs: Years; d: daily; w: week; m: month; qod: every other day. *Outcome (1) New vertebral fractures out of total subjects; (2) New hip fractures out of total subjects; (3) New nonvertebral nonhip fractures out of total subjects.
Zoledronate had the lowest OR, but no significant difference was found in comparison with any other bisphosphonate. Nine studies were included in the analysis concerning the efficacy for secondary prevention of new hip fractures. Alendronate had the lowest OR at 0.38, followed by zoledronate and risedronate, and the OR for etidronate surpassed 1. However, none of the five bisphosphonates exhibited a statistically significant superiority to placebo (Figure 4). Moreover, comparison among the five studied bisphosphonates did not reveal any statistically significant difference either.

Nine studies investigated the effectiveness of bisphosphonates for the secondary prevention of new nonvertebral nonhip fractures. A Forest plot for new nonvertebral nonhip fractures is shown in Figure 5. According to our results, the efficacies of bisphosphonates were similar to those of placebo (alendronate: OR = 0.79, 95% CrI 0.21–1.6; ibandronate: OR = 1.1, 95% CrI 0.51–2.4; risedronate: OR = 0.6, 95% CrI 0.27–1.3; zoledronate: OR = 0.50, 95% CrI 0.16–1.6; etidronate: OR = 0.96, 95% CrI 0.34–2.3). No statistically significant difference was found in a comparison among the five studied bisphosphonates.

3.4. Comparisons between Direct and Indirect Evidence. The node-splitting method comparing indirect and direct evidence for a specific comparison of bisphosphonates and its Bayesian P value were used to demonstrate the inconsistency between the direct and indirect comparisons in our results. The general consistency from direct and indirect evidence was identified in the comparison of ibandronate and risedronate for secondary prevention of vertebral fracture with corresponding P values of 0.730, 0.737, and 0.737, respectively, with no significant inconsistency found (Figure 6).

3.5. Relative Ranking of Five Interventions. SUCRAs were applied to provide a probability rank for each bisphosphonate. The results for the five bisphosphonates are shown in Table 2. As mentioned above, the lower the SUCRA of an active
intervention, the more efficient it is, indicating a lower incidence of secondary osteoporotic fractures. With respect to the primary endpoint of new vertebral fractures, alendronate was the best treatment based on its lowest probability ranking (14.6%), followed by zoledronate (15.3%) and etidronate (22.1%). In terms of new hip fractures, alendronate ranked
lowest (18.5%), followed by zoledronate (43.1%), and risedronate (52.5%). However, zoledronate ranked lowest (16.6%) regarding the incidence of new nonvertebral nonhip fractures, followed by risedronate (23.8%) and alendronate (44.1%).

4. Discussion

Our meta-analysis demonstrated that bisphosphonates significantly reduced the risk of secondary new vertebral, hip, and nonvertebral nonhip fractures. Alendronate was identified as the most efficacious for secondary prevention of vertebral and hip fractures by probability plot and SUCRA calculation, while zoledronate showed better performance for nonvertebral non-hip fracture prevention. However, for all fracture endpoints combined, no significant difference was found among the five bisphosphonates. To our knowledge, this is the first Bayesian network meta-analysis to compare the efficacies of the five most commonly used bisphosphonates for the secondary prevention of osteoporotic fractures. The results could be used as an important reference for decision making in clinical scenarios.

The goal of osteoporosis management is to prevent osteoporotic fractures, but for those who have had sustained an osteoporotic fracture, it is more urgent to prevent a secondary fracture. This is because patients with an osteoporotic fracture are more likely to experience a recurrent fracture, with a marked increase in morbidity and mortality compared to those among patients without fractures [31–35]. For patients with hip fractures, the estimated 1- and 2-year morality rates in South Korea were reported to be 16% and 28%, respectively, and the prevalence of osteoporotic fractures as well as the associated societal costs are estimated to increase markedly given that the aging index is expected to increase up to 213.8% by 2030 [36]. In mainland China, the pooled estimate for the 1-year mortality rate following hip fracture was 13.96% between the years 2000 and 2018 [37]. Also, vertebral fractures occurred with a high prevalence in the very elderly population, with an estimated incidence of 30.4% according to the vertebral fracture assessment [38]. Bisphosphonates are well-studied antiresorptive medications that are widely approved and recommended as a first line choice for osteoporosis in postmenopausal women and older populations. Several high-quality RCTs have demonstrated the efficacy of individual bisphosphonates for secondary fracture prevention, but few sufficient comparisons have been carried out due to a lack of large-scale direct trials.

Currently available meta-analyses and reviews have largely focused on anti-osteoporosis medication for primary fracture prevention [9–11]. A network meta-analysis reported that teriparatide, bisphosphonates, and denosumab are most effective at reducing the risk of fragility fractures, even though the differences in efficacy across the studied interventions were small [39]. A similar Bayesian network meta-analysis that compared 10 therapies (the five bisphosphonates in our study along with clodronate, raloxifene, parathyroid hormone, denosumab, and strontium ranelate) was initiated by Wang et al. [5], and they suggested that zoledronate and parathyroid hormone have the highest probability of providing the best

![Forest plot for new nonvertebral nonhip fractures (A, Placebo; B, Alendronate; C, Ibandronate; D, Risedronate; E, Zoledronate; F, Etidronate).](image-url)
of the relative effect of bisphosphonates (alendronate, ibandronate, risedronate, and zoledronate), no active intervention was considered to be more effective than any other one for preventing fracture [40].

In a systematic review by the Cochrane library about “alendronate in secondary prevention of osteoporotic fractures” [41], which indicated that both clinically important and statistically significant reductions in vertebral, nonvertebral, hip, and wrist fractures were observed with alendronate for secondary prevention of fracture, the definition of secondary prevention was “women whose bone density was at least 2 SD values below the peak bone mass or who had experienced previous vertebral compression fractures”. In another systematic review and meta-analysis by Saito et al. that included patients without osteoporotic fractures, secondary fragility fractures were prevented by several anti-osteoporotic drugs, among which bisphosphonates and PTH were most effective at preventing nonvertebral fractures [42]. However, this is not exactly in accordance with the strictly defined secondary prevention of osteoporotic fractures as in the Fracture Liaison Service (FLS) project initiated by International Osteoporosis Foundation (IOF) [43–45] and clinical practice, which is the target population we would like to investigate in our study.

Therefore, previous studies enrolled patients both with and without existing osteoporotic fractures, and conclusions about different interventions for secondary fracture prevention cannot be inferred from findings in patients with varying fracture risks.

Moreover, since the comparative efficacies of bisphosphonates for secondary fracture prevention are hard to assess by direct comparison through clinical trials, the possible ranking applied in this network meta-analysis may provide a valuable prediction. Alendronate showed better performance in our study for secondary prevention of vertebral and hip fractures, while zoledronate was recommended for nonvertebral nonhip fracture prevention, which is partially in accordance with a network meta-analysis conducted by Jansen et al. in primary prevention [46]. Jansen et al.’s study suggested that alendronate, ibandronate, risedronate, and zoledronate are all effective for the prevention vertebral fracture with zoledronate as a better choice and alendronate ranked first for preventing hip fracture. The discrepancy in efficacy might be due to differences in the inclusion criteria and the baseline characteristics of the study population.

Both men and postmenopausal women with osteoporotic fractures were enrolled in the analysis, which included two alendronate trials, one ibandronate trial, and one zoledronate trial with 148 men altogether. In addition, most existing fractures are prevalent vertebral fractures. In our preliminary literature search, one article about zoledronate use in patients with a previous hip fracture was identified, but it was then excluded because the median treatment duration was less than 2 years. In addition, in the analysis of alendronate, different doses were given in the included trials (from 5 mg/d to 10 mg/d or 70 mg/w) which might underestimate the efficacy in fracture prevention.

There are some limitations in the present meta-analysis. First, the diagnostic criterion of new vertebral fracture has not been uniform across different studies, given that both morphometric and clinical vertebral fractures are applied in fracture detection, which might lead to potential bias. Secondly, a relatively small number of new nonvertebral nonhip fractures was investigated in relevant studies, which lacked some key comparisons. Consequently, the results for this endpoint should be interpreted with caution. Third, the baseline characteristics and the compliance varied among different studies, which may influence the detection of the investigated events, and trial durations also differed, possibly adding heterogeneity or bias to the results. Lastly, the methodological quality was somewhat limited because whether allocation concealment was conducted properly was unclear in 12 studies [13–16, 22–25, 27–30]. Also, a high risk of incomplete outcome data bias was observed because the method of last-observation was carried out for the missing data in some studies [13, 14, 16, 23, 24, 26, 29].

5. Conclusions

By combining all the direct and indirect evidence, our results suggest that bisphosphonates showed significant efficacy for secondary prevention of new vertebral fractures, while
alendronate had the highest probability of successful performance in the secondary prevention of vertebral and hip fractures compared with the other four bisphosphonates that treat patients with existing osteoporotic fractures. However, more prospective, direct studies with large sample sizes, high quality, and longer follow-up periods are needed to confirm the results of our study.

Data Availability

The datasets generated and analyzed during the present study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Supplementary Materials

Figure S1. Pairwise meta-analysis of bisphosphonates versus placebo ((a) new vertebral fractures, (b) new hip fractures, and (c) new non-vertebral non-hip fractures). Figure S2. Sensitivity analysis showed ((a) new vertebral fractures, (b) new hip fractures, and (c) new non-vertebral non-hip fractures). Figure S3. Publication bias ((a) new vertebral fractures, (b) new hip fractures, and (c) new non-vertebral non-hip fractures). (Supplementary Materials)

References

[1] B. Larjani, M. R. M. Tehrani, Z. Hamidi, A. Soltani, and M. Fajouhi, "Osteoporosis, prevention, diagnosis and treatment," Journal of Reproduction & Infertility, vol. 6, 2005.
[2] S. R. Cummings and L. J. Melton, "Epidemiology and outcomes of osteoporotic fractures," Lancet, vol. 359, pp. 1761–1767, 2002.
[3] A. S. Nazrun, M. N. Tzar, S. A. Mokhtar, and I. N. Mohamed, "A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality," Therapeutics and Clinical Risk Management, vol. 10, pp. 937–948, 2014.
[4] M. Iki, Y. Fujita, K. Kouda et al., "Increased risk of osteoporotic fracture in community-dwelling elderly men 20 or more years after gastrectomy: the fujisawa-kyo osteoporosis risk in men (FORMEN) cohort study," Bone, vol. 127, pp. 250–259, 2019.
[5] G. Wang, L. Sui, P. Gai, G. Li, X. Qi, and X. Jiang, "The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: which therapies work best? a network meta-analysis," Bone Joint Research, vol. 6, no. 7, pp. 452–463, 2017.
[6] J. Watson, L. Wise, and J. Green, "Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005," European Journal of Clinical Pharmacology, vol. 63, no. 9, pp. 843–849, 2007.
[7] A. Makhzoum, L. Petriw, M. Sattin, and T. Towheed, "OP0049 Systematic review of randomized controlled trials evaluating bisphosphonates for the prevention and treatment of glucocorticoid-induced osteoporosis," BMJ Journals, vol. 76, no. 2, 2017.
[8] D. A. Hanley, M. R. McClung, K. S. Davison et al., "Western osteoporosis alliance clinical practice series: evaluating the balance of benefits and risks of long-term osteoporosis therapies," American Journal of Medicine, vol. 130, no. 7, pp. 862.e1–862.e7, 2017.
[9] L. Chen, G. Wang, F. Zheng, H. Zhao, and H. Li, "Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials," Osteoporosis International, vol. 26, no. 9, pp. 2355–2363, 2015.
[10] J. Peng, Y. Liu, L. Chen et al., "Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: a meta-analysis," Pakistan Journal of Medicine Sciences, vol. 32, no. 2, pp. 499–504, 2016.
[11] J.-H. Byun, S. Jang, S. Lee et al., "The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis," Journal of Bone Metabolism, vol. 24, no. 1, pp. 37–49, 2017.
[12] C.-L. Liu, H.-C. Lee, C.-C. Chen, and D.-Y. Cho, "Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis," Clinical and Investigative Medicine, vol. 40, no. 3, 146 pages, 2017.
[13] J.-Y. Reginster, H. W. Minne, O. H. Sorensen et al., "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. vertebral efficacy with risedronate therapy (VERT) study group," Osteoporosis International, vol. 11, no. 1, pp. 83–91, 2000.
[14] T. Nakamura, T. Nakano, M. Ito et al., "Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis," Calcul Tissue International, vol. 93, no. 2, pp. 137–146, 2013.
[15] R. X. Ji, J. Su, X. S. Guo, Z. Q. Yu, H. X. Liu, and C. Q. Liu, "Clinical study on the effect of alendronate sodium in the prevention of second fracture in patients with osteoporotic vertebral fracture," Zhejiang Journal of Traumatic Surgery, vol. 18, pp. 823–825, 2013.
[16] T. Nakamura, M. Fukunaga, T. Nakano et al., "Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in efficacy to osteoporosis; ZONE study)," Osteoporosis International, vol. 28, no. 1, pp. 389–398, 2017.
[17] J. P. Higgins and A. Whitehead, "Borrowing strength from external trials in a meta-analysis," Statistics in Medicine, vol. 15, no. 24, pp. 2733–2749, 1996.
[18] M. Zeytinoglu, R. K. Jain, and T. J. Vokes, "Vertebral fracture assessment: enhancing the diagnosis, prevention, and treatment of osteoporosis," Bone, vol. 104, pp. 54–65, 2017.
[19] T. Lumley, "Network meta-analysis for indirect treatment comparisons," Statistics in Medicine, vol. 21, no. 16, pp. 2313–2324, 2002.
[20] S. Dias, N. J. Welton, D. M. Caldwell, and A. E. Ades, "Checking consistency in mixed treatment comparison meta-analysis," Statistics in Medicine Banner, vol. 29, pp. 932–944, 2010.
[21] G. Salanti, A. E. Ades, and J. P. Ioannidis, "Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial," Journal of Clinical Epidemiology, vol. 64, no. 2, pp. 163–171, 2011.
22 T. Storm, G. Thamsborg, T. Steiniche, H. K. Genant, and O. H. Sorensen, "Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis," *New England Journal of Medicine*, vol. 322, no. 18, pp. 1265–1271, 1990.

23 N. B. Watts, S. T. Harris, H. K. Genant et al., "Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis," *New England Journal of Medicine*, vol. 323, no. 2, pp. 73–79, 1990.

24 D. M. Black, S. R. Cummings, D. B. Karpf et al., "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures," *The Lancet*, vol. 348, no. 9041, pp. 1535–1541, 1996.

25 B. Clemmesen, P. Ravn, B. Zegels, A. N. Taquet, C. Christiansen, and J. Y. Reginster, "A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis," *Osteoporosis International*, vol. 7, no. 5, pp. 488–495, 1997.

26 S. T. Harris, N. B. Watts, H. K. Genant et al., "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial vertebral efficacy with risedronate therapy (VERT) study group," *JAMA*, vol. 282, no. 14, pp. 1344–1352, 1999.

27 C. H. Chesnutt, A. Skag, C. Christiansen et al., "Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis," *Journal of Bone and Mineral Research*, vol. 19, no. 8, pp. 1241–1249, 2004.

28 K. Kushida, M. Shiraki, T. Nakamura et al., "Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study," *Journal of Bone and Mineral Metabolism*, vol. 22, no. 5, pp. 462–468, 2004.

29 R. Recker, J. A. Stakkestad, C. H. Chesnutt et al., "Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis," *Bone*, vol. 34, no. 5, pp. 890–899, 2004.

30 M. Q. Wang, "The value of Alendronate in the prevention of second fracture in patients with osteoporotic vertebral fracture," *China Health Standard Management*, vol. 7, pp. 95–96, 2016.

31 L. Si, T. M. Winzenberg, and A. J. Palmer, "A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures," *Osteoporosis International*, vol. 25, no. 1, pp. 51–60, 2014.

32 J. H. Yoo, S. H. Moon, Y. C. Ha et al., "Osteoporotic fracture: 2015 position statement of the korean society for bone and mineral research," *Journal of Bone Metabolism*, vol. 22, no. 4, pp. 175–181, 2015.

33 L.-A. Fraser, G. Ioannidis, J. D. Adachi et al., "Fragility fractures and the osteoporosis care gap in women: the canadian multicentre osteoporosis study," *Osteoporosis International*, vol. 22, no. 3, pp. 789–796, 2011.

34 T. Willson, S. Nelson, J. Newbold, R. Nelson, and J. LaFleur, "The clinical epidemiology of male osteoporosis: a review of the recent literature," *Clinical Epidemiology*, vol. 7, pp. 65–76, 2015.

35 J. E. Sale, D. Beaton, and E. Bogoch, "Secondary prevention after an osteoporosis-related fracture: an overview," *Clinics in Geriatric Medicine*, vol. 30, no. 2, pp. 317–332, 2014.

36 J. Kim, E. Lee, S. Kim, and T. J. Lee, "Economic burden of osteoporotic fracture of the elderly in south korea: a national survey," *Value in Health Regional Issues*, vol. 9, pp. 36–41, 2016.

37 Z. Cui, H. Feng, X. Meng et al., "Age-specific 1-year mortality rates after hip fracture based on the populations in mainland china between the years 2000 and 2018: a systematic analysis," *Archives of Osteoporosis*, vol. 14, no. 1, 2019.

38 L. A. Bastos, D. R. B. Tavares, J. E. F. Okazaki et al., "High prevalence of vertebral fracture in a very elderly community-dwelling: longevous project," *Journal of Clinical Densitometry*, 2019.

39 M. H. Murad, M. T. Drake, R. J. Mullan et al., "Clinical review. comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis," *The Journal of Clinical Endocrinology & Metabolism*, vol. 97, no. 6, pp. 1871–1880, 2012.

40 J. Sanderson, M. Martyn-St James, J. Stevens et al., "Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis," *Bone*, vol. 89, pp. 52–58, 2016.

41 G. A. Wells, A. Cranney, J. Peterson et al., "Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women," *Cochrane Database of Systematic Reviews*, 2008.

42 T. Saito, J. M. Sterbenz, S. Malay, L. Zhong, M. P. MacEachern, and K. C. Chung, "Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis," *Osteoporosis International*, vol. 28, no. 12, pp. 3289–3300, 2017.

43 S. D. Berry, D. Misra, M. T. Hannan, and D. P. Kiel, "Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting," *Aging Clinical and Experimental Research*, vol. 22, no. 3, pp. 231–237, 2010.

44 R. Dimitriou, G. M. Calori, and P. V. Giannoudis, "Improving patients' outcomes after osteoporotic fractures," *International Journal of Clinical Rheumatology*, vol. 7, pp. 109–124, 2012.

45 K. Akesson, D. Marsh, P. J. Mitchell et al., "Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle," *Osteoporosis International*, vol. 24, no. 8, pp. 2135–2152, 2013.

46 J. P. Jansen, G. J. D. Bergman, J. Huels, and M. Olson, "The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis," *Seminars in Arthritis and Rheumatism*, vol. 40, no. 4, pp. 275–284.e2, 2011.